Erythropoietin receptor induces a paclitaxel resistance phenotype in mammary adenocarcinoma cells

Zsóková,Erika; Ilkovičová,Lenka; Kimáková,Patrícia; Fecková,Barbora; Solár,Peter

doi:10.3892/or.2019.7222

Erythropoietin receptor induces a paclitaxel resistance phenotype in mammary adenocarcinoma cells

Authors:
- Erika Zsóková
- Lenka Ilkovičová
- Patrícia Kimáková
- Barbora Fecková
- Peter Solár
View Affiliations

Affiliations: Department of Cell Biology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, SK‑04011 Košice, Slovak Republic, Institute of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK‑04011 Košice, Slovak Republic
Published online on: July 5, 2019 https://doi.org/10.3892/or.2019.7222
Pages: 1149-1160

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

While erythropoietin (EPO) regulates erythropoiesis, the erythropoietin receptor (EPOR) has been identified in many non‑hematopoietic cells, including cancer. Our previous study demonstrated that overexpression of EPOR altered the cell growth and the sensitivity of RAMA 37 breast cancer cells to tamoxifen. Indeed, results of the present study uncovered the role of EPOR in the resistance of EPOR‑overexpressing RAMA 37‑28 cells to paclitaxel chemotherapy. In this regard, EPOR silencing in the presence of paclitaxel therapy decreased RAMA 37‑28 cell proliferation, confirming its role in the sensitivity or resistance of RAMA 37‑28 cells to paclitaxel. Notably, compared to parental RAMA 37 cells, RAMA 37‑28 cells also showed a lower rate of apoptosis induced by paclitaxel, as monitored by caspase 3/7 activation and Annexin V by IncuCyte ZOOM system. Moreover, enhanced activation of signaling pathways mediated by pERK1/2 in RAMA 37‑28 cells as detected by western blot analysis was demonstrated to be essential for paclitaxel resistance.

View Figures

View References

1	Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 23:5960–5972. 2005. View Article : Google Scholar : PubMed/NCBI
2	Henke M, Laszig R, Rube C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar : PubMed/NCBI
3	Watowich SS: The erythropoietin receptor: Molecular structure and hematopoietic signaling pathways. J Investig Med. 59:1067–1072. 2011. View Article : Google Scholar : PubMed/NCBI
4	Debeljak N, Solar P and Sytkowski AJ: Erythropoietin and cancer: The unintended consequences of anemia correction. Front Immunol. 5:5632014. View Article : Google Scholar : PubMed/NCBI
5	Arcasoy MO, Jiang X and Haroon ZA: Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun. 307:999–1007. 2003. View Article : Google Scholar : PubMed/NCBI
6	Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR and Jelkmann W: Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer. 43:510–519. 2007. View Article : Google Scholar : PubMed/NCBI
7	Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG and Elliott S: Absence of functional EpoR expression in human tumor cell lines. Blood. 115:4254–4263. 2010. View Article : Google Scholar : PubMed/NCBI
8	Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM and Brem H: Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 6:609–621. 2007. View Article : Google Scholar : PubMed/NCBI
9	Orr JW Jr: What constitutes the ‘optimal’ treatment environment of women with gynecologic cancer? Gynecol Oncol. 89:1–3. 2003. View Article : Google Scholar : PubMed/NCBI
10	Larsson AM, Jirstrom K, Fredlund E, Nilsson S, Rydén L, Landberg G and Påhlman S: Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res. 15:5552–5559. 2009. View Article : Google Scholar : PubMed/NCBI
11	Volgger B, Kurz K, Zoschg K, Theurl I, Ciresa-König A, Marth C and Weiss G: Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer. Anticancer Res. 30:3721–3726. 2010.PubMed/NCBI
12	Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, Neumann D, Rönnstrand L and Påhlman S: EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation. Biochem Biophys Res Commun. 445:163–169. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ilkovičová L, Trošt N, Szentpéteriová E, Solár P, Komel R and Debeljak N: Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen. Int J Oncol. 51:737–746. 2017. View Article : Google Scholar : PubMed/NCBI
14	Niyazi M, Niyazi I and Belka C: Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol. 2:42007. View Article : Google Scholar : PubMed/NCBI
15	Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, et al: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the breast cancer-anemia and the value of erythropoietin (BRAVE) study. J Clin Oncol. 26:592–598. 2008. View Article : Google Scholar : PubMed/NCBI
16	Aapro M, Gascon P, Patel K, Rodgers GM, Fung S, Arantes LH Jr and Wish J: Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: A historical perspective. Front Pharmacol. 9:14982019. View Article : Google Scholar : PubMed/NCBI
17	Leyland-Jones B, Bondarenko I, Nemsadze G, Smirnov V, Litvin I, Kokhreidze I, Abshilava L, Janjalia M, Li R, Lakshmaiah KC, et al: A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 34:1197–1207. 2016. View Article : Google Scholar : PubMed/NCBI
18	Nagarkar R, Gascón P, Šmakal M, Syrigos K, Barrios C, Cárdenas Sánchez J, Zhang L, Tomita D, Park J and De Oliveira Brandao C: A double-blind, randomized, placebo-controlled phase 3 noninferiority study of darbepoetin alfa for anemia in advanced NSCLC. MA02.05. J Thorac Oncol. 13 (Suppl):S3592018. View Article : Google Scholar
19	Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M and Blau CA: Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells. 27:2353–2361. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hadland BK and Longmore GD: Erythroid-stimulating agents in cancer therapy: Potential dangers and biologic mechanisms. J Clin Oncol. 27:4217–4226. 2009. View Article : Google Scholar : PubMed/NCBI
21	Jelkmann W, Bohlius J, Hallek M and Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 67:39–61. 2008. View Article : Google Scholar : PubMed/NCBI
22	Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G and Begley CG: Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 107:1892–1895. 2006. View Article : Google Scholar : PubMed/NCBI
23	Elliott S, Swift S, Busse L, Scully S, Van G, Rossi J and Johnson C: Epo receptors are not detectable in primary human tumor tissue samples. PLoS One. 8:e680832013. View Article : Google Scholar : PubMed/NCBI
24	Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB and Rich JN: Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer. 1:50–61. 2010. View Article : Google Scholar : PubMed/NCBI
25	Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X and Acs G: RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol. 174:1504–1514. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ueda F, Tago K, Tamura H and Funakoshi-Tago M: Three tyrosine residues in the erythropoietin receptor are essential for janus kinase 2 V617F mutant-induced tumorigenesis. J Biol Chem. 292:1826–1846. 2017. View Article : Google Scholar : PubMed/NCBI
27	Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R and Zeuner A: Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res. 73:6393–6400. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, Acs G and Xu X: Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 31:1649–1660. 2012. View Article : Google Scholar : PubMed/NCBI
29	Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ and Feldman L: An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res. 7:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
30	Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M and Lappin TR: Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res. 8:615–626. 2010. View Article : Google Scholar : PubMed/NCBI
31	Wu G, Qin XQ, Guo JJ, Li TY and Chen JH: AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458. 2014.PubMed/NCBI
32	Chun E and Lee KY: Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 315:771–779. 2004. View Article : Google Scholar : PubMed/NCBI
33	Solar P, Feldman L, Jeong JY, Busingye JR and Sytkowski AJ: Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer. 122:281–288. 2008. View Article : Google Scholar : PubMed/NCBI